Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02369458 · ClinicalTrials.gov registry record · Phase 2
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02369458 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT02369458, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti-tumor activity in these patients.
Interventions
- DRUG Mitomycin-C
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02369458
The ClinicalTrials.gov registry entry for NCT02369458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mitomycin-C is the first listed.
NCT02369458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02369458 about?
NCT02369458 is a clinical study titled "Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies". No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti...
What is the current status of trial NCT02369458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-04-14. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT02369458?
The interventions under investigation include: Mitomycin-C (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT02369458?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.